Nevertheless, it is crucial to recognise the significant intratumoural heterogeneity of TROP2 expression, as strong expression was observed in only about a quarter of all TROP2‐positive CRC cases, which seems to differ from other cancer types such as TNBC [46]. This evidence concerns the gene TACSTD2 and cancer.